{"id":338,"date":"2019-10-21T08:52:58","date_gmt":"2019-10-21T06:52:58","guid":{"rendered":"http:\/\/asso-cpdis.com\/?p=338"},"modified":"2019-12-18T18:19:05","modified_gmt":"2019-12-18T17:19:05","slug":"dejeuner-du-mardi-12-novembre-vie-scientifique-et-financiere-dune-start-up","status":"publish","type":"post","link":"http:\/\/asso-cpdis.com\/index.php\/2019\/10\/21\/dejeuner-du-mardi-12-novembre-vie-scientifique-et-financiere-dune-start-up\/","title":{"rendered":"D\u00e9jeuner du mardi 12 novembre : \u00ab\u00a0Vie scientifique et financi\u00e8re d’une start up\u00a0\u00bb"},"content":{"rendered":"

Mardi 12 novembre 2019 :<\/p>\n

\u00ab\u00a0Vie scientifique et financi\u00e8re d’une start up\u00a0\u00bb<\/strong><\/p>\n

Orateur invit\u00e9 : Dr. Gilles AVENARD<\/strong>, PDG de ACTICOR BIOTECH<\/p>\n

M\u00e9decin h\u00e9matologiste de formation, il a une longue carri\u00e8re dans l\u2019industrie pharmaceutique aussi bien en grand groupe (Hoechst Marion Roussel) que dans une soci\u00e9t\u00e9 moyenne (LFB) puis dans des start up (BIOALLIANCE qu\u2019il a cr\u00e9\u00e9) et ACTICOR BIOTECH (qu\u2019il dirige).<\/p>\n

\n
Il a \u00e9t\u00e9 par ailleurs Vice Pr\u00e9sident de FRANCE BIOTECH et de l\u2019AMIPS.<\/div>\n
<\/div>\n
Il nous parlera de la fa\u00e7on dont une biotech se d\u00e9veloppe tant sur le plan scientifique (d\u00e9veloppement d\u2019un produit) que sur le plan financier (lev\u00e9e de fonds, p\u00e9rennit\u00e9 de l\u2019entreprise).<\/div>\n
De fa\u00e7on plus large il nous parlera des probl\u00e9matiques des start up du m\u00e9dicament (entrepreneuriales, accords et partenariats,\u00a0\u2026)<\/div>\n
Enfin il nous conseillera sur \u00ab\u00a0comment investir dans une biotech ?\u00a0\u00bb.<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Mardi 12 novembre 2019 : \u00ab\u00a0Vie scientifique et financi\u00e8re d’une start up\u00a0\u00bb Orateur invit\u00e9 : Dr. Gilles AVENARD, PDG de ACTICOR BIOTECH M\u00e9decin h\u00e9matologiste de formation, il a une longue carri\u00e8re dans l\u2019industrie pharmaceutique aussi bien en grand groupe (Hoechst Marion Roussel) que dans une soci\u00e9t\u00e9 moyenne (LFB) puis dans des start up (BIOALLIANCE qu\u2019il […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-338","post","type-post","status-publish","format-standard","hentry","category-evenements-2018"],"_links":{"self":[{"href":"http:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/posts\/338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/comments?post=338"}],"version-history":[{"count":1,"href":"http:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/posts\/338\/revisions"}],"predecessor-version":[{"id":339,"href":"http:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/posts\/338\/revisions\/339"}],"wp:attachment":[{"href":"http:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/media?parent=338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/categories?post=338"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/asso-cpdis.com\/index.php\/wp-json\/wp\/v2\/tags?post=338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}